Add this topic to your myFT Digest for news straight to your inbox
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Regulator authorises treatment for sickle cell disease and beta thalassaemia
Shares soar after biotech company announces landmark use of technology in clinical trial
Biotech group’s promising results help it defy broader investor fears over sector
Combination treatment offers safer option for patients suffering from deadly illness
US stocks make little progress at start of the week
Pharmaceutical companies accept lower sales as they shift to personalised treatments
Technology-heavy index powered by Yellen comments on plan to raise rates slowly
US stocks edge higher after two days of declines
Advances in innovation help sector add to 2014 gains, bucking wider January sell-off
Search for improved therapies intensifies
US equities boosted by consumer confidence data, but gains fade
Deals activity dominates S&P 500 movements
Vertex therapy could be multibillion-dollar product
Acquisition has considerable advantages in spite of its mind-boggling price
International Edition